Viropharma news from FierceBiotech

ViroPharma has forged a deal to buy Lev Pharmaceuticals - a developer focused on developing inflammatory therapies -- for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a Read more...

After observing serious safety problems in a Phase II trial, Wyeth and ViroPharma are dropping development of HCV-796. In August the companies halted study of the drug when the data showed elevated Read more...

> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by Read more...

The analysts have been picking over Wyeth's carcass over the past few days as they assess a string of woeful developments that have left the company stripped of three of its leading drug candidates. Read more...

That's not all the bad news for Wyeth today. In yet another blow, the company and its partner ViroPharma have stopped dosing patients with HCV-796, a Phase II hepatitis C drug candidate. The decision Read more...

Based on strong product pipelines, positive clinical data and impressive partnerships with big drug companies, The Motley Fool profiles four small biopharm companies that could emerge as Read more...

> U.S. regulators have strongly suggested that Vasogen undertake a study to confirm the clinical data on Celacade before filing for approval of the heart medication. Report

> EndoCeutics has pulled its IPO, citing market conditions and a changeup in its schedule for clinical trials. The Canadian biotech is developing hormone therapies for breast cancer and endocrine-related disorders. …

Read more...

Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 …

Read more...

> Novartis has announced that Switzerland has approved Lucentis for age-related macular degeneration, marking its first European approval for the drug. The FDA approved Lucentis two months ago. Novartis says it will start supplying the drug in September. Report

> ViroPharma shares were buoyed by positive results from an early trial of its drug for hepatitis C. After 14 days of doses of HCV-796 …

Read more...

Wyeth will buy $10 million in ViroPharma shares after the two collaborators achieved proof-of-concept stage for an experimental hepatitis C therapy. Preliminary data from Phase I should be available by the end of August. Report